Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2861
Sophia F. Magkouta, C. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Charalampos Moschos, M. Iliopoulou, K. Psarra, I. Kalomenidis
{"title":"Targeting of CSF1R abrogates Lewis Lung adenocarcinoma-induced malignant pleural effusion","authors":"Sophia F. Magkouta, C. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Charalampos Moschos, M. Iliopoulou, K. Psarra, I. Kalomenidis","doi":"10.1183/13993003.congress-2018.pa2861","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2861","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"80 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76685845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2872
Sang-Ha Kim, Beomsu Shin, S. Lee, M. Lee, W. Lee, S. Yong
{"title":"Comparison of pleural fluid pH measurements: blood gas analyzer, pH indicator stick, litmus paper, and point-of-care testing for blood gases","authors":"Sang-Ha Kim, Beomsu Shin, S. Lee, M. Lee, W. Lee, S. Yong","doi":"10.1183/13993003.congress-2018.pa2872","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2872","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91272984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.OA498
R. Asciak, R. Mercer, R. Hallifax, Maged Hassan, N. Kanellakis, J. Wrightson, I. Psallidas, N. Rahman
Non-draining septated pleural effusions limit effective drainage via indwelling pleural catheters (IPC). Aim: To retrospectively analyse whether previous talc pleurodesis attempt increases chances of a non-draining septated pleural effusion after IPC insertion. Method IPC outcomes and complications for IPC insertions were analysed. ‘MPE group’ were IPC insertions for malignant pleural effusion(MPE), ‘non-MPE group’ were IPC insertions for hepatic hydrothorax(3% overall), benign pleuritis(3%), heart failure(2%), other(2.5%). Mesothelioma cases were analysed separately in view of the possibility of increased pleural tumour-induced fibrin deposition within the pleural space. Results: 202 IPC insertions were analysed: MPE group(n=181), mean age 68 years(SD 13.9), 48% female (n=87); non-MPE group(n=21), mean age 70 years(SD 10.8) (p=0.4), 29%(n=6) female (p=0.09). Overall, 2.7% (n=2) and 4.7% (n=6) of patients with and without prior talc respectively developed non-draining septated pleural effusion (p=0.47). Of these, 2(25%) patients had heterogeneously septated pleural effusion at IPC insertion, and they had not received prior talc, 75%(n=6) developed septation while IPC was in situ. Conclusion: There was no significant difference in rates of non-draining septated effusions between patients who had received prior talc and those who had not, although limited by the retrospective study design and small numbers.
{"title":"Does talc increase risk of non-draining septated pleural effusion after indwelling pleural catheter insertion?","authors":"R. Asciak, R. Mercer, R. Hallifax, Maged Hassan, N. Kanellakis, J. Wrightson, I. Psallidas, N. Rahman","doi":"10.1183/13993003.CONGRESS-2018.OA498","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA498","url":null,"abstract":"Non-draining septated pleural effusions limit effective drainage via indwelling pleural catheters (IPC). Aim: To retrospectively analyse whether previous talc pleurodesis attempt increases chances of a non-draining septated pleural effusion after IPC insertion. Method IPC outcomes and complications for IPC insertions were analysed. ‘MPE group’ were IPC insertions for malignant pleural effusion(MPE), ‘non-MPE group’ were IPC insertions for hepatic hydrothorax(3% overall), benign pleuritis(3%), heart failure(2%), other(2.5%). Mesothelioma cases were analysed separately in view of the possibility of increased pleural tumour-induced fibrin deposition within the pleural space. Results: 202 IPC insertions were analysed: MPE group(n=181), mean age 68 years(SD 13.9), 48% female (n=87); non-MPE group(n=21), mean age 70 years(SD 10.8) (p=0.4), 29%(n=6) female (p=0.09). Overall, 2.7% (n=2) and 4.7% (n=6) of patients with and without prior talc respectively developed non-draining septated pleural effusion (p=0.47). Of these, 2(25%) patients had heterogeneously septated pleural effusion at IPC insertion, and they had not received prior talc, 75%(n=6) developed septation while IPC was in situ. Conclusion: There was no significant difference in rates of non-draining septated effusions between patients who had received prior talc and those who had not, although limited by the retrospective study design and small numbers.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90098888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2891
R. Banka, E. Mishra
Introduction: VASD is a patient reported outcome assessing dyspnea intensity, consisting of a 100mm horizontal line anchored at 0mm with ‘Not breathless at all’ and at 100mm with ‘Worst possible breathlessness’. Although it is a validated measure of dyspnea change with pleural fluid drainage, the optimal duration of measurement following aspiration is not well established and there appears to be a significant placebo effect after 24 hours. Aim: To assess whether routine measurement of 7-DVQ post pleural aspiration is i.acceptable to patients and has a good(>70%)response rate ii. Assess relationship between volume of pleural fluid drained and mean 7-DVQ. Methods: Between Sept 2017 and Jan 2018, consecutive patients undergoing pleural aspiration in pleural clinic at NNUH were enrolled to fill up 7-DVQ. Baseline VASD was recorded before the aspiration and subsequently the patient was asked to complete it at home for 7 days. Results: Of 23 patients who underwent aspiration,17 questionnaires were returned, of which data for analysis were available from 16 patients. Demographics are summarised in Table 1. Mean VASD at baseline and at end of 7 days was 64 mm(SD 28) and 46 mm(SD 21)respectively. Mean decrease in VASD at end of 7 days was 19 mm(SD 14). Correlation between volume of fluid aspirated and decrease in 7-DVQ was 0.5(p=0.03) Conclusion: This study shows that 7-DVQ as a measure to quantify change in dyspnea post aspiration correlates well with amount of fluid aspirated and baseline dyspnea.A response rate of 73% suggests that 7-DVQ is an acceptable measure for patients.
{"title":"Assessing breathlessness following pleural fluid drainage using the Visual Analogue Scale for Dyspnoea(VASD) over 1 week(7-DVQ)","authors":"R. Banka, E. Mishra","doi":"10.1183/13993003.CONGRESS-2018.PA2891","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2891","url":null,"abstract":"Introduction: VASD is a patient reported outcome assessing dyspnea intensity, consisting of a 100mm horizontal line anchored at 0mm with ‘Not breathless at all’ and at 100mm with ‘Worst possible breathlessness’. Although it is a validated measure of dyspnea change with pleural fluid drainage, the optimal duration of measurement following aspiration is not well established and there appears to be a significant placebo effect after 24 hours. Aim: To assess whether routine measurement of 7-DVQ post pleural aspiration is i.acceptable to patients and has a good(>70%)response rate ii. Assess relationship between volume of pleural fluid drained and mean 7-DVQ. Methods: Between Sept 2017 and Jan 2018, consecutive patients undergoing pleural aspiration in pleural clinic at NNUH were enrolled to fill up 7-DVQ. Baseline VASD was recorded before the aspiration and subsequently the patient was asked to complete it at home for 7 days. Results: Of 23 patients who underwent aspiration,17 questionnaires were returned, of which data for analysis were available from 16 patients. Demographics are summarised in Table 1. Mean VASD at baseline and at end of 7 days was 64 mm(SD 28) and 46 mm(SD 21)respectively. Mean decrease in VASD at end of 7 days was 19 mm(SD 14). Correlation between volume of fluid aspirated and decrease in 7-DVQ was 0.5(p=0.03) Conclusion: This study shows that 7-DVQ as a measure to quantify change in dyspnea post aspiration correlates well with amount of fluid aspirated and baseline dyspnea.A response rate of 73% suggests that 7-DVQ is an acceptable measure for patients.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77719372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2860
R. Mercer, D. McCracken, R. Asciak, R. Hallifax, Maged Hassan, E. Bedawi, N. Rahman
Introduction: Pleural fluid (PF) cytology was previously sufficient to guide oncological treatment. In the current field of personalised medicine, this may not be the case and it is frequently necessary to obtain a tissue sample even when the PF cytology demonstrates malignant cells. This raises the question of the role of PF cytology in the diagnostic pathway of patients with malignant pleural effusion. Aims & Method: All patients who had a procedure performed by the pleural service between 2015 - 2017 were included. Those with PF demonstrating malignant cells were reviewed to determine whether further tissue was required. Those with concurrent pleural histological samples were excluded. Results: 107 patients had positive PF cytology. No further testing was needed in 49 patients; 33 already had a pathological diagnosis and 16 were too unwell for treatment or followed up elsewhere. PF was sufficient to test for receptor or mutation status in 33/58 (57%) patients, 19 (33%) required further pleural biopsies and 6 (10%) underwent alterative procedures to obtain tissue. 52/58 patients had adenocarcinoma cells in the PF. Conclusions: PF cytology was sufficient for definitive oncological treatment in 57% of patients. Further work is needed to determine characteristics which would highlight which patients are likely to need further tests to guide treatments and in which patients PF will be sufficient.
{"title":"In the era of personalised medicine, is pleural fluid cytology sufficient for oncological treatment?","authors":"R. Mercer, D. McCracken, R. Asciak, R. Hallifax, Maged Hassan, E. Bedawi, N. Rahman","doi":"10.1183/13993003.congress-2018.pa2860","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2860","url":null,"abstract":"Introduction: Pleural fluid (PF) cytology was previously sufficient to guide oncological treatment. In the current field of personalised medicine, this may not be the case and it is frequently necessary to obtain a tissue sample even when the PF cytology demonstrates malignant cells. This raises the question of the role of PF cytology in the diagnostic pathway of patients with malignant pleural effusion. Aims & Method: All patients who had a procedure performed by the pleural service between 2015 - 2017 were included. Those with PF demonstrating malignant cells were reviewed to determine whether further tissue was required. Those with concurrent pleural histological samples were excluded. Results: 107 patients had positive PF cytology. No further testing was needed in 49 patients; 33 already had a pathological diagnosis and 16 were too unwell for treatment or followed up elsewhere. PF was sufficient to test for receptor or mutation status in 33/58 (57%) patients, 19 (33%) required further pleural biopsies and 6 (10%) underwent alterative procedures to obtain tissue. 52/58 patients had adenocarcinoma cells in the PF. Conclusions: PF cytology was sufficient for definitive oncological treatment in 57% of patients. Further work is needed to determine characteristics which would highlight which patients are likely to need further tests to guide treatments and in which patients PF will be sufficient.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"101 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80468038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2894
Ivan Škopljanac, Ivana Šegrt, K. Miše, Emilija Lozo Vukovac, Anita Tolic Biocina
Introduction: Malignant pleural mesothelioma is a rare tumour commonly associated with asbestos exposure however with increasing incidence and poor survival. The standard first-line chemotherapy regimen is the combination of cisplatin and pemetrexed, with median overall survival of 13 months. Other therapeutic options like surgery, radiation and immunotherapy are currently limited therefore patient s performance status and histological subtype are the only prognostic factors (Scherpereel A. et al. EurRespir J 2010;35: 479-95, Scherpereel A. EurRespir J.2017 Mar 15;49(3). Aim and Objectives: The aim of study was to compare the patient9s survival depending on whether they received chemotherapy or not. Methods: We identified retrospectively 24 patients diagnosed with pleural mesothelioma in Department of Pulmonology, Clinical Hospital Center Split, Croatia evaluating their management, whether they were treated by cisplatin/pemetrexed or solely palliative care as a result of poor performance status or refusal of any specific treatment. Kaplan-Meier survival analysis was used (MedCalc Software ver. 18). Results: The overall median survival (OS) time was 14,6 months. A pronounced OS benefit for palliative care versus cisplatin/pemetrexed was observed, 17 vs 8 months, respectively; HR, 0,3665 ; 95% CI, 0,14 to 0,90 ; P = 0,0047, Fig. 1. Conclusions: Chemotherapeutic treatment did not show better outcomes than solely palliative treatment. Future prospective randomized controlled studies are necessary to optimize the treatment of malignant mesothelioma.
恶性胸膜间皮瘤是一种罕见的肿瘤，通常与石棉暴露有关，但发病率上升，生存率低。标准的一线化疗方案是顺铂联合培美曲塞，中位总生存期为13个月。其他治疗选择，如手术、放疗和免疫治疗目前有限，因此患者的运动状态和组织学亚型是唯一的预后因素(Scherpereel A. et al.)。张建军，张建军。中国生物医学工程学报，2010;35:479-95。目的和目的:研究的目的是比较患者是否接受化疗的生存率。方法:我们回顾性分析了24例在克罗地亚斯普利特临床医院中心肺病科诊断为胸膜间皮瘤的患者，评估了他们的治疗情况，无论他们是由于表现不佳或拒绝任何特定治疗而接受顺铂/培美曲塞治疗还是单纯姑息治疗。采用Kaplan-Meier生存分析(MedCalc Software ver.)。18)。结果:总中位生存期(OS)为14.6个月。与顺铂/培美曲塞相比，姑息治疗的OS获益明显，分别为17个月和8个月;Hr, 0,3665;95% CI为0.14 ~ 0.90;P = 0.0047，图1。结论:化疗并不比单纯姑息治疗有更好的预后。未来有必要进行前瞻性随机对照研究，以优化恶性间皮瘤的治疗。
{"title":"Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma","authors":"Ivan Škopljanac, Ivana Šegrt, K. Miše, Emilija Lozo Vukovac, Anita Tolic Biocina","doi":"10.1183/13993003.congress-2018.pa2894","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2894","url":null,"abstract":"Introduction: Malignant pleural mesothelioma is a rare tumour commonly associated with asbestos exposure however with increasing incidence and poor survival. The standard first-line chemotherapy regimen is the combination of cisplatin and pemetrexed, with median overall survival of 13 months. Other therapeutic options like surgery, radiation and immunotherapy are currently limited therefore patient s performance status and histological subtype are the only prognostic factors (Scherpereel A. et al. EurRespir J 2010;35: 479-95, Scherpereel A. EurRespir J.2017 Mar 15;49(3). Aim and Objectives: The aim of study was to compare the patient9s survival depending on whether they received chemotherapy or not. Methods: We identified retrospectively 24 patients diagnosed with pleural mesothelioma in Department of Pulmonology, Clinical Hospital Center Split, Croatia evaluating their management, whether they were treated by cisplatin/pemetrexed or solely palliative care as a result of poor performance status or refusal of any specific treatment. Kaplan-Meier survival analysis was used (MedCalc Software ver. 18). Results: The overall median survival (OS) time was 14,6 months. A pronounced OS benefit for palliative care versus cisplatin/pemetrexed was observed, 17 vs 8 months, respectively; HR, 0,3665 ; 95% CI, 0,14 to 0,90 ; P = 0,0047, Fig. 1. Conclusions: Chemotherapeutic treatment did not show better outcomes than solely palliative treatment. Future prospective randomized controlled studies are necessary to optimize the treatment of malignant mesothelioma.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"241 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91115564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2895
Eleftherios D. Papazoglou, R. Jagirdar, E. Pitaraki, O. Kotsiou, C. Hatzoglou, K. Gourgoulianis, S. Zarogiannis
{"title":"Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells","authors":"Eleftherios D. Papazoglou, R. Jagirdar, E. Pitaraki, O. Kotsiou, C. Hatzoglou, K. Gourgoulianis, S. Zarogiannis","doi":"10.1183/13993003.CONGRESS-2018.PA2895","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2895","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89296299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2892
N. Živković, A. Ljilja, Nina-Petra Novak, N. Tudorić
The diagnostic method of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) for the confirmation of extrathoracic malignant disease dissemination into mediastinal lymph nodes has been proven as highly efficient (sensitivity 93%, specificity 100%). The aim of this research was to carry out a retrospective study of the medical records of patients with newly developed mediastinal/hilar lymphadenopathy (ML) and previously diagnosed extrathoracic malignant disease, select the patients with previously diagnosed breast carcinoma, and analyze the results of EBUS-TBNA. The retrospective, single-center clinical observational study was conducted in the period from January 2015 to August 2017, in which the EBUS-TBNA results were analyzed for 77 patients who had met the inclusion criteria. A malignant etiology of the ML was confirmed in 39/77 patients (50.64%). Patients with previously diagnosed breast carcinoma showed a divergence within this group. A malignant etiology of the ML was confirmed in 10/14 patients (71.42%), and a benign one in 3/14 patients (21.42%). In one patient with reactive lymphadenopathy and pulmonary parenchymal infiltration, primary lung carcinoma was confirmed by thoracotomy. Two patients showed signs of reactive/granulomatous ML during chemotherapy with paclitaxel, and in one patient sarcoidosi was confirmed. To conclude, in spite of the high percentage of a malignant etiology of newly developed ML in patients with previously diagnosed breast carcinoma, their cytological verification is necessary due to the possibility of a reactive/granulomatous lymph node reaction, especially in patients undergoing chemotherapy with paclitaxel.
{"title":"EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma","authors":"N. Živković, A. Ljilja, Nina-Petra Novak, N. Tudorić","doi":"10.1183/13993003.congress-2018.pa2892","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2892","url":null,"abstract":"The diagnostic method of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) for the confirmation of extrathoracic malignant disease dissemination into mediastinal lymph nodes has been proven as highly efficient (sensitivity 93%, specificity 100%). The aim of this research was to carry out a retrospective study of the medical records of patients with newly developed mediastinal/hilar lymphadenopathy (ML) and previously diagnosed extrathoracic malignant disease, select the patients with previously diagnosed breast carcinoma, and analyze the results of EBUS-TBNA. The retrospective, single-center clinical observational study was conducted in the period from January 2015 to August 2017, in which the EBUS-TBNA results were analyzed for 77 patients who had met the inclusion criteria. A malignant etiology of the ML was confirmed in 39/77 patients (50.64%). Patients with previously diagnosed breast carcinoma showed a divergence within this group. A malignant etiology of the ML was confirmed in 10/14 patients (71.42%), and a benign one in 3/14 patients (21.42%). In one patient with reactive lymphadenopathy and pulmonary parenchymal infiltration, primary lung carcinoma was confirmed by thoracotomy. Two patients showed signs of reactive/granulomatous ML during chemotherapy with paclitaxel, and in one patient sarcoidosi was confirmed. To conclude, in spite of the high percentage of a malignant etiology of newly developed ML in patients with previously diagnosed breast carcinoma, their cytological verification is necessary due to the possibility of a reactive/granulomatous lymph node reaction, especially in patients undergoing chemotherapy with paclitaxel.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73555500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2870
A. Sharifi, D. Amir
{"title":"Red cell distribution width value as a novel biomarker for exudative pleural fluid.","authors":"A. Sharifi, D. Amir","doi":"10.1183/13993003.congress-2018.pa2870","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2870","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"243 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72936288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2875
S. Ra, W. Kwon, Yongjik Lee, C. Park, H. Cha, B. Kang, Taehoon Lee, Y. Jegal, J. Ahn, Y. Chee, K. Seo
{"title":"Rotation Aiding (RA’s) technique for EBUS-TBNA biopsy of intrathoracic lymph node: a comparison of conventional Jab method","authors":"S. Ra, W. Kwon, Yongjik Lee, C. Park, H. Cha, B. Kang, Taehoon Lee, Y. Jegal, J. Ahn, Y. Chee, K. Seo","doi":"10.1183/13993003.congress-2018.pa2875","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2875","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80773406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：